# Oral Arsenic Trioxide for NPM1-mutated AML

> **NCT04689815** · PHASE2 · UNKNOWN · sponsor: **The University of Hong Kong** · enrollment: 50 (estimated)

## Conditions studied

- NPMc+ AML

## Interventions

- **DRUG:** Oral Arsenic Trioxide Formulation

## Key facts

- **NCT ID:** NCT04689815
- **Lead sponsor:** The University of Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-01-01
- **Primary completion:** 2023-12-31
- **Final completion:** 2024-12-31
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2022-10-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04689815

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04689815, "Oral Arsenic Trioxide for NPM1-mutated AML". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04689815. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*